-
Johnson&Johnson unbinds Kenvue's $600 million deal to bid farewell to the skincare and beauty industry
Recently, Kenvue (KVUE. US) announced on its official website that Johnson&Johnson (JNJ. US) will sell its remaining 9.5% stake in the company to Goldman Sachs and JPMorgan Chase in a debt to equity ... -
Legendary Biology is rumored to have received a billion dollar acquisition offer, and the industry expects Johnson&Johnson to participate in the competition
On July 12th, the US stock market analysis website Seeking Alpha reported that according to Street Insider, domestic biotech company Legendary Biotech received a merger offer and hired investment ban ... -
Johnson&Johnson's drug Zebaike has been approved in China
On October 21st, Johnson&Johnson announced that its drug Zebeko (Nilaparivabiraterone tablets) has been officially approved by the National Medical Products Administration. As the first and only appr ... -
Kaken signs Stat6 global licensing agreement with Johnson&Johnson
Japanese pharmaceutical company Kaken announced on December 26th that it has signed a license agreement with Johnson&Johnson for the global development, production, and commercialization of the STAT6 ...